K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, P. Home: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. In: Diabetes Care. 29, Nr. 6, 2006, S. 1269–1274, doi:10.2337/dc05-1365, PMID 16732007.
K. Hermansen, P. Fontaine, K. K. Kukolja, V. Peterkova, G. Leth, M. A. Gall: Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. In: Diabetologia. 47 (4), 2004, S. 622–629, doi:10.1007/s00125-004-1365-z, PMID 15298338.
europa.eu
ema.europa.eu
EPAR Levemir®; Deutsche Zusammenfassung des Zulassungsberichtes der Europäischen Arzneimittelagentur: (PDF)
P. Kurtzhals, L. Schäffer, A. Sørensen, C. Kristensen, I. Jonassen, C. Schmid, T. Trüb: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. In: Diabetes. 49, Nr. 6, 2000, S. 999–1005, PMID 10866053.
K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, P. Home: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. In: Diabetes Care. 29, Nr. 6, 2006, S. 1269–1274, doi:10.2337/dc05-1365, PMID 16732007.
K. Hermansen, P. Fontaine, K. K. Kukolja, V. Peterkova, G. Leth, M. A. Gall: Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. In: Diabetologia. 47 (4), 2004, S. 622–629, doi:10.1007/s00125-004-1365-z, PMID 15298338.
